Search
Respiratory syncytial virus (RSV) is a global cause of severe respiratory morbidity and mortality in infants. While preventive and therapeutic interventions are being developed, including antivirals, vaccines and monoclonal antibodies, little is known about the global molecular epidemiology of RSV. INFORM is a prospective, multicenter, global clinical study performed by ReSViNET to investigate the worldwide molecular diversity of RSV isolates collected from children less than 5 years of age.
Four The Kids Research Institute Australia researchers have received prestigious fellowships and four significant cohort studies led or co-led by The Kids have received key grants under two new funding programs supported by the State Government’s Future Health Research and Innovation (FHRI) Fund.
Staphylococcus aureus is a common cause of bacteremia, yet the epidemiology and predictors of poor outcome remain inadequately defined in childhood. ISAIAH (Invasive Staphylococcus aureus Infections and Hospitalizations in children) is a prospective, cross-sectional study of S. aureus bacteremia in children hospitalized in Australia and New Zealand over 24 months.
Sepsis is a significant cause of mortality for children in Australia, particularly affecting young children, those with pre-existing health conditions and Aboriginal and Torres Strait Islander populations. The transition from hospital to home can be challenging for survivors, often leaving long-term impacts unaddressed.
Western Australian kids will have access to a needle-free nasal flu vaccine for the first time in 2026 as part of a new initiative to boost vaccination rates against the life-threatening virus.
Dr Asha Bowen, Head of Skin Health at the Wesfarmers Centre of Vaccines and Infectious Diseases, has been awarded a 2018 Fellowship as part of the prestigious L’Oréal-UNESCO Women in Science program.
As many as a quarter of Australian babies aren’t getting vaccinated on time, leaving them at risk of developing life-threatening illnesses such as whooping cough when they are most vulnerable.
Babies are most vulnerable to life-threatening diseases in their first few weeks of life, yet current vaccines can’t be given until two months of age.
Newborn babies and their fragile immune systems struggle to fight off nasty infections such as septicaemia, pneumonia and gastroenteritis.
Six weeks, nine community visits and 380 kids – it’s a wrap for round one of the StoP Trial!